First-Line Treatment Use and Survival Outcomes for Patients With Primary Advanced or Recurrent Endometrial Cancer in Alberta, Canada
Characteristics such as age and comorbidities impacted first-line systemic therapy use in primary A/R EC. Patients who were older, with high-grade histology, stage IV without surgery, and receiving platinum monotherapy had the shortest OS. Effective treatment options are needed to prolong survival for primary A/R EC.
Authors
- Sophia Pin (ORCID: https://orcid.org/0000-0003-2264-044X)
- Justin Riemer (ORCID: https://orcid.org/0000-0001-8950-6638)
- Patrick C. Turnbull
- Winson Y. Cheung (ORCID: https://orcid.org/0000-0002-3679-4290)
- Jacob McGee (ORCID: https://orcid.org/0000-0003-3210-0682)
- Dylan Edmund O'Sullivan (ORCID: https://orcid.org/0000-0002-2562-0017)
- Diana Martins
Institutions
- University of Alberta (CA)
- University of Calgary (CA)
- GlaxoSmithKline (Canada) (CA)
Publication Details
- Journal
- Journal of Obstetrics and Gynaecology Canada
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1016/j.jogc.2025.103107
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00